ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TROP-2 Antibody-drug Conjugate OBI-902

Its studies are led by OBI Pharma.

Furthest: phase 2, since Aug 4, 20251 company-led study, 1 open or runningNext primary completion: Feb 8, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
OBI Pharma11 open or runningphase 2since Aug 4, 2025Aug 4, 2025Feb 8, 2029phase 2 · NCT07124117

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2025First study: phase 2 study in Advanced Solid TumorFirst studyNCT07124117 · 147 planned · United States, Taiwan

Ahead

  1. Feb 8, 2029Primary completion: phase 2 study in Advanced Solid TumorNCT07124117

TargetBeta

TACSTD2 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1), site-specifically ”NCIt, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
sacituzumab tirumotecanMerckphase 350
datopotamab deruxtecanruleAstraZenecaphase 329
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07124117Advanced Solid Tumor · United States, Taiwan2RecruitingFeb 8, 2029147

How it is read

Names in the registry

  • “OBI-902”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.